TNM seventh edition: What's new, what's changed

Sobin, Leslie H.; Compton, Carolyn C.

doi:10.1002/cncr.25537

Cited by 423 publications

(171 citation statements)

References 24 publications

Supporting

Mentioning

158

Contrasting

Order By: Relevance

“…These patients underwent medical examinations, including computed tomography and endoscopy, and were shown not to have any pancreatic or cancerous diseases. Tumor stages were assessed according to the Union for International Cancer Control classification system 97 . Peripheral blood (7 ml) was obtained from each patient at the time of diagnosis or before surgery and from the healthy volunteers.…”

Section: Methodsmentioning

confidence: 99%

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Imamura

Komatsu

Ichikawa

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

This study explored decreased tumor suppressor microRNA (miRNA) plasma levels in pancreatic cancer (PCa) patients to clarify their potential as novel biomarkers and therapeutic targets. We used the microRNA array-based approach to select candidates by comparing plasma levels between PCa patients and healthy volunteers. Six down-regulated miRNAs (miR-107, miR-126, miR-451, miR-145, miR-491-5p, and miR-146b-5p) were selected. Small-and large-scale analyses using samples from 100 PCa patients and 80 healthy volunteers revealed that miR-107 was the most down-regulated miRNA in PCa patients compared with healthy volunteers (P < 0.0001; area under the receiver-operating characteristic curve, 0.851). A low miR-107 plasma level was significantly associated with advanced T stage, N stage, and liver metastasis and was an independent factor predicting poor prognosis in PCa patients (P = 0.0424; hazard ratio, 2.95). miR-107 overexpression in PCa cells induced G1/S arrest with the production of p21 and inhibited cell proliferation through the transcriptional regulation of Notch2. In vivo, the restoration and maintenance of the miR-107 plasma level significantly inhibited tumor progression in mice. Depletion of the tumor suppressor miR-107 in plasma relates to tumor progression and poor outcomes. The restoration of the plasma miR-107 level might be a novel anticancer treatment strategy for PCa.Pancreatic cancer (PCa) is the fourth leading cause of cancer-related death in Japan and the United States 1 and the seventh worldwide 2 . PCa is one of the most aggressive cancer types and constitutes a global health problem, with more than 330,000 cancer-related deaths annually 2 . Although perioperative chemo-and/or radiotherapy regimens, surgical techniques and perioperative management have greatly progressed, PCa continues to present an extremely poor prognosis. Even now, the median survival time of PCa patients is 5 to 8 months, and their 5-year survival rate is less than 10%. This is because PCa develops with no symptoms, local invasiveness, or metastases to distant organs in the early stage of its clinical course [3][4][5] . Therefore, novel early diagnostic tools and effective treatment strategies are urgently needed to improve the survival rate of PCa patients.Because understanding the molecular mechanisms of tumorigenesis and identifying clinical biomarkers and molecular targets for PCa contribute to improving the management of this lethal disease, several studies have attempted to detect the biological factors involved in the malignant potential of PCa 6, 7 . Nevertheless, in clinical settings, no molecule has been used as an early diagnostic biomarker, and only a few molecules have been

show abstract

Section: Methodsmentioning

confidence: 99%

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Imamura

Komatsu

Ichikawa

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

“…The risk stratification of patients with GIST is based on the location of the tumor, its size, and its mitotic index (13). For gastric localisation, a tumor, between the size of 2 and 5 cm, and a mitotic index < 5/50 hpf, has a very low risk -1.9% (5).…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Stromal Tumor Associated with Myasthenia Gravis: A Case Report

Nedelcu

Dumitrescu

2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Introduction: Gastrointestinal stromal tumors (GIST) represent less than 1% of all gastrointestinal tumors. The GIST diagnosis in a patient with a newly discovered myasthenia gravis (MG) raises the problem of evolution and treatment. Case Presentation: We present the case of a 58-year-old patient, who has been diagnosed with MG on December 2015 at emergency clinical county hospital Brasov, Romania. After further investigations, a localized gastric GIST was discovered. The treatment was surgical (January 2016) and the one-year evolution after the surgery was without relapse. Genetic mutations in the KIT and PDGFR genes were investigated. Conclusions: GIST may be accidentally discovered in asymptomatic patients. Genetic mutation examinations are needed in order to provide evidence. MG in association with GIST is rare and raises problems of diagnosis and treatment.

show abstract

“…Tumor staging was performed according to the TNM classification system [15]. Histologic classification of GC was carried out according to the Lauren classification system [16].…”

Section: Methodsmentioning

confidence: 99%

Characteristic <b><i>miR-24</i></b> Expression in Gastric Cancers among Atomic Bomb Survivors

et al. 2015

View full text Add to dashboard Cite

Objective: To elucidate the mechanism of radiation-induced cancers, we analyzed the expression profiles of microRNAs extracted from formalin-fixed paraffin-embedded (FFPE) gastric cancer (GC) tissue samples from atomic bomb survivors. Methods: The expression levels of miR-21, miR-24, miR-34a, miR-106a, miR-143, and miR-145 were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results: The expression of microRNAs was measured by qRT-PCR in a Hiroshima University Hospital cohort comprising 32 patients in the high-dose-exposed group and 18 patients in the low-dose-exposed group who developed GC after the bombing. The GC cases showing high expression of miR-24, miR-143, and miR-145 were more frequently found in the high-dose-exposed group than in the low-dose-exposed group. We next performed qRT-PCR of miR-24, miR-143, and miR-145 in a cohort from the Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital comprising 122 patients in the high-dose-exposed group and 48 patients in the low-dose-exposed group who developed GC after the bombing. High expressions of miR-24 and miR-143 were more frequently found in the high-dose-exposed group than in the low-dose-exposed group. Multivariate analysis demonstrated that only high expression of miR-24 was an independent predictor for the exposure status. Conclusion: These results suggest that the measurement of miR-24 expression from FFPE samples is useful to identify radiation-associated GC.

show abstract

TNM seventh edition: What's new, what's changed

Abstract: The seventh edition of the TNM Classification of Malignant Tumors contains several new and modified component classifications. The purpose of this communication was to briefly summarize these changes.

Cited by 423 publications

References 24 publications

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Gastrointestinal Stromal Tumor Associated with Myasthenia Gravis: A Case Report

Characteristic <b><i>miR-24</i></b> Expression in Gastric Cancers among Atomic Bomb Survivors

Contact Info

Product

Resources

About